-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, Shanghai Qilu Ruige Pharmaceutical Research and Development Co.
, Ltd.
("Rige Pharmaceutical") and Eli Lilly and Company of the United States jointly announced that they have reached a research cooperation and patent licensing agreement.
The two parties will conduct preclinical drug development, clinical research and Close cooperation in commercialization will jointly develop innovative therapies for metabolic diseases
.
According to the terms of the agreement, Rieger Pharmaceuticals granted Eli Lilly the United States a license for the intellectual property rights of Rieger Pharmaceuticals, and Eli Lilly can choose to extend the license
.
Eli Lilly will be responsible for clinical development, production and commercialization outside of Greater China (including Mainland China, Hong Kong, Macau and Taiwan), while Ruige Pharmaceutical will retain the aforementioned rights and interests in Greater China
.
In this cooperation, Rieger Pharmaceuticals is expected to receive a total of 50 million U.
S.
dollars in advance, including part of the equity investment; in addition, it will also receive up to 1.
5 billion U.
S.
dollars in potential pre-clinical, clinical development and commercialization milestone payments, as well as individual Global sales share from digits to the lower two digits
.
According to public information, Ruige Pharmaceutical is an innovative drug research and development platform
.
Committed to the research and development of innovative drugs (first-in-class) and similar drugs (best-in-class) with independent intellectual property rights in the fields of tumor, autoimmunity and metabolism
.
In the three and a half years since its establishment, Rege Pharmaceuticals has targeted the "long-term" target of the pharmaceutical industry with its own AI-assisted new drug development CARD platform and has developed innovative drugs with clinically differentiated advantages
.
Therefore, for this cooperation between the two parties, analysis believes that while reflecting the core technology and research capabilities of Rieger Pharmaceuticals, it will also further expand Eli Lilly to provide more treatment methods for patients with metabolic diseases worldwide
.
It is worth noting that this cooperation is not the first time Eli Lilly has cooperated with a domestic pharmaceutical company to obtain a new drug authorization
.
In recent years, the multinational pharmaceutical company that has been digging more treasures in China is none other than Eli Lilly.
Last year, it obtained the authorization of 3 new drugs.
In addition to continuing to expand the global cooperation based on Sintilizumab with Cinda, it also started from Junshi has obtained the right to develop the new crown neutralizing antibody.
In addition, it has also obtained the right to develop FCN-338, a selective inhibitor of B-cell lymphoma-2 (BCL-2) from Fosun Pharma, outside of Greater China.
.
Analysts believe that behind the license out of local pharmaceutical companies, it means that China’s new drug R&D strength is constantly improving, and it no longer only relies on foreign companies to "import" innovative drugs; it also means that Chinese local innovative companies are exploring subdivision of technology fields.
Cooperate in development and continuously improve the efficiency of new drug development
.
It is understood that in the near future, Shanghai Pharmaceuticals has also announced an exclusive license agreement with HUYABIO, authorizing it to obtain the rights to manufacture, develop and commercialize SPH6162 outside of China
.
This is the first overseas licensing project of Shanghai Pharmaceuticals, and it also marks a milestone in the company's significant progress in R&D and innovation capabilities
.
In general, behind the license out of local pharmaceutical companies, it means that China's new drug research and development capabilities are gradually being recognized by overseas markets
.
In the future, as China's local innovative companies continue to improve their innovation capabilities and innovations continue to emerge, this type of cooperation will continue to increase
.
, Ltd.
("Rige Pharmaceutical") and Eli Lilly and Company of the United States jointly announced that they have reached a research cooperation and patent licensing agreement.
The two parties will conduct preclinical drug development, clinical research and Close cooperation in commercialization will jointly develop innovative therapies for metabolic diseases
.
According to the terms of the agreement, Rieger Pharmaceuticals granted Eli Lilly the United States a license for the intellectual property rights of Rieger Pharmaceuticals, and Eli Lilly can choose to extend the license
.
Eli Lilly will be responsible for clinical development, production and commercialization outside of Greater China (including Mainland China, Hong Kong, Macau and Taiwan), while Ruige Pharmaceutical will retain the aforementioned rights and interests in Greater China
.
In this cooperation, Rieger Pharmaceuticals is expected to receive a total of 50 million U.
S.
dollars in advance, including part of the equity investment; in addition, it will also receive up to 1.
5 billion U.
S.
dollars in potential pre-clinical, clinical development and commercialization milestone payments, as well as individual Global sales share from digits to the lower two digits
.
According to public information, Ruige Pharmaceutical is an innovative drug research and development platform
.
Committed to the research and development of innovative drugs (first-in-class) and similar drugs (best-in-class) with independent intellectual property rights in the fields of tumor, autoimmunity and metabolism
.
In the three and a half years since its establishment, Rege Pharmaceuticals has targeted the "long-term" target of the pharmaceutical industry with its own AI-assisted new drug development CARD platform and has developed innovative drugs with clinically differentiated advantages
.
Therefore, for this cooperation between the two parties, analysis believes that while reflecting the core technology and research capabilities of Rieger Pharmaceuticals, it will also further expand Eli Lilly to provide more treatment methods for patients with metabolic diseases worldwide
.
It is worth noting that this cooperation is not the first time Eli Lilly has cooperated with a domestic pharmaceutical company to obtain a new drug authorization
.
In recent years, the multinational pharmaceutical company that has been digging more treasures in China is none other than Eli Lilly.
Last year, it obtained the authorization of 3 new drugs.
In addition to continuing to expand the global cooperation based on Sintilizumab with Cinda, it also started from Junshi has obtained the right to develop the new crown neutralizing antibody.
In addition, it has also obtained the right to develop FCN-338, a selective inhibitor of B-cell lymphoma-2 (BCL-2) from Fosun Pharma, outside of Greater China.
.
Analysts believe that behind the license out of local pharmaceutical companies, it means that China’s new drug R&D strength is constantly improving, and it no longer only relies on foreign companies to "import" innovative drugs; it also means that Chinese local innovative companies are exploring subdivision of technology fields.
Cooperate in development and continuously improve the efficiency of new drug development
.
It is understood that in the near future, Shanghai Pharmaceuticals has also announced an exclusive license agreement with HUYABIO, authorizing it to obtain the rights to manufacture, develop and commercialize SPH6162 outside of China
.
This is the first overseas licensing project of Shanghai Pharmaceuticals, and it also marks a milestone in the company's significant progress in R&D and innovation capabilities
.
In general, behind the license out of local pharmaceutical companies, it means that China's new drug research and development capabilities are gradually being recognized by overseas markets
.
In the future, as China's local innovative companies continue to improve their innovation capabilities and innovations continue to emerge, this type of cooperation will continue to increase
.
